Life sciences company signs university vaccine deal

Life sciences company Aptamer Group has signed a licensing agreement with the University of Glasgow for exclusive rights to its synthetic binders to develop swine flu vaccines.

Under the agreement, the university will use Aptamer’s panel of optimer binders as vaccine adjuvants with commercialisation anticipated within the next 12 months.

York-based Aptamer will receive a 10% royalty on all future revenues from any vaccines incorporating the licensed optimers, creating a scalable and global revenue stream.

This partnership provides Aptamer access to the $1.75bn global swine vaccine market, an industry experiencing sustained demand for improved animal health solutions.

Dr Arron Tolley, CEO of Aptamer, said: “This licensing deal represents an important milestone in the commercialisation of our optimer technology. It demonstrates our ability to deliver high-value solutions across diverse sectors and builds on our strategic focus of monetising optimer-based assets beyond our core focus in human health. With growing demand for advanced animal health solutions, this partnership creates a global pathway to recurring revenues while validating the robustness and versatility of our Optimer platform.

 “This agreement reinforces Aptamer’s broader commercial strategy of leveraging its proprietary platform across multiple verticals, including targeted drug delivery for human therapeutics, diagnostics, personal care, research reagents, and now veterinary vaccines, to generate long-term shareholder value.”